Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mindy M Mickelson

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Clinical and Translational Science|January 10, 2025
Multidisciplinary stakeholder engagement in a type 2 diabetes comparative effectiveness study utilizing real-world dataElizabeth H Golembiewski, Mindy M Mickelson, Juan P Brito, et al.
Journal of General Internal Medicine|April 24, 2025
In Pursuit of Person-Centered Medicine: How Do People with Type 2 Diabetes Choose Glucose-Lowering Medications? A Qualitative StudyElizabeth H Golembiewski, Xinyuan Ning, Mindy M Mickelson, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|January 20, 2025
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease RiskRozalina G McCoy, Kavya Sindhu Swarna, Joshua J Neumiller, et al.
Journal of the American Heart Association|July 17, 2025
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular RiskYihong Deng, Eric C Polley, Jeph Herrin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 27, 2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular RiskJoshua J Neumiller, Jeph Herrin, Kavya Sindhu Swarna, et al.
Ophthalmology. Retina|August 7, 2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideAndrew J Barkmeier, Yihong Deng, Kavya Sindhu Swarna, et al.
Ophthalmology. Retina|May 12, 2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic RetinopathyAndrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 4, 2026
Lower Extremity Complications in Adults with Type 2 Diabetes treated with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas: An Emulated Target TrialRozalina G McCoy, Kavya Sindu Swarna, Eric C Polley, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 13, 2025
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease RiskUrja N Kalathiya, Jeph Herrin, Kavya Sindu Swarna, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 16, 2026
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 DiabetesJoshua J Neumiller, Yihong Deng, Kavya Sindhu Swarna, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Clinical and Translational Science|January 10, 2025
Multidisciplinary stakeholder engagement in a type 2 diabetes comparative effectiveness study utilizing real-world dataElizabeth H Golembiewski, Mindy M Mickelson, Juan P Brito, et al.
Journal of General Internal Medicine|April 24, 2025
In Pursuit of Person-Centered Medicine: How Do People with Type 2 Diabetes Choose Glucose-Lowering Medications? A Qualitative StudyElizabeth H Golembiewski, Xinyuan Ning, Mindy M Mickelson, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|January 20, 2025
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease RiskRozalina G McCoy, Kavya Sindhu Swarna, Joshua J Neumiller, et al.
Journal of the American Heart Association|July 17, 2025
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular RiskYihong Deng, Eric C Polley, Jeph Herrin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 27, 2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular RiskJoshua J Neumiller, Jeph Herrin, Kavya Sindhu Swarna, et al.
Ophthalmology. Retina|August 7, 2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideAndrew J Barkmeier, Yihong Deng, Kavya Sindhu Swarna, et al.
Ophthalmology. Retina|May 12, 2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic RetinopathyAndrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 4, 2026
Lower Extremity Complications in Adults with Type 2 Diabetes treated with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas: An Emulated Target TrialRozalina G McCoy, Kavya Sindu Swarna, Eric C Polley, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 13, 2025
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease RiskUrja N Kalathiya, Jeph Herrin, Kavya Sindu Swarna, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 16, 2026
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 DiabetesJoshua J Neumiller, Yihong Deng, Kavya Sindhu Swarna, et al.
Pageof 2